A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Inclusion Criteria:

Female participants, 18 years or older
Measurable disease per radiographic evaluation
Performance status 0 or 1
Available archival tissue sample (within 2 years) or a fresh tumor biopsy may be required
Adequate organ, cardiac, and bone marrow function

Dose escalation

Participants with breast cancer:

Locally advanced or metastatic triple negative breast cancer (ER-negative, PgR-negative, and HER2-negative according to ASCO/CAP guidelines) with disease progression
No available alternative or curative therapy
Participants may have received any number of prior therapies for advanced/recurrent and progressive disease

Participants with ovarian cancer:

Locally advanced or metastatic ovarian cancer with disease progression
No available alternative or curative therapy
Participants may have received any number of prior therapies for advanced/recurrent and progressive disease

Dose expansion

Participants with breast cancer:

Locally advanced or metastatic triple negative breast cancer (ER-negative, PgR-negative, and HER2-negative according to ASCO/CAP guidelines)
Disease progression after no more than 3 prior lines of therapy

Participants with ovarian cancer:

Locally advanced or metastatic ovarian cancer that is platinum-resistant
Disease progression after no more than 3 prior lines of therapy

Exclusion Criteria:

Received a live, attenuated vaccine within 4 weeks prior to first study treatment
Prior anticancer treatment including approved agents, systemic radiotherapy, or investigational therapy within 4 weeks prior first study treatment
Cancer other than the disease under study within 2 years prior to study entry, except for some cancers with a low risk of spreading like non-melanoma skin cancers
Inability to swallow oral medications
Participant is breastfeeding, pregnant, or expects to become pregnant during the study
Active autoimmune disease or documented history of autoimmune disease within 2 years prior to first study treatment
History of peptic ulcer or stomach bleeding within 6 months prior to first study treatment
Use of drugs contraindicated by the protocol within 4 weeks prior to and during study treatment
Prior treatment with drugs that suppress the immune system within 2 weeks prior to first study treatment
Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid - CSF (leptomeningeal disease)
HIV, Hepatitis B, and C test results negative prior to first study treatment
Major surgery within 4 weeks prior to first study treatment
Participants who have previously received maximum cumulative lifetime anthracycline dosage or baseline ejection fraction <50% (on heart echography)